Business
Journey Medical Corporation Announces Emrosi™ Featured on “The Balancing Act” Airing on Lifetime TV
National TV Segment Highlights FDA-Approved Treatment for Rosacea Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for
About this update from Fortress Biotech, Inc.
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"National TV Segment Highlights FDA-Approved Treatment for Rosacea","length":65,"tagName":"p"},{"type":"text","content":"Segment premiered on Monday, June 9 and will be rebroadcast on Thursday, June 19, at 7:30 a.m. PT/ ET","length":101,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., June 09, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”, “we”, or “our”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that a new segment of “The Balancing Act®” airing on Lifetime TV and sponsored by the Company featured Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), its FDA-approved treatment for inflammatory lesions of rosacea in adults. The segment premiered nationwide on Monday, June 9, at 7:30 a.m. PT / ET and provided expert insights on lifestyle considerations and treatment options for managing rosacea.","length":811,"tagName":"p"},{"type":"text","content":"“We’re proud to see Emrosi featured on ‘The Balancing Act,’ bringing national visibility to what we believe is a potential paradigm shift in the treatment of rosacea,” said Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Journey Medical. “This segment is an important opportunity to educate patients, caregivers and healthcare providers about Emrosi’s unique formulation and benefits, as well as our broader commitment to advancing dermatologic care through innovative, patient-focused solutions.”","length":519,"tagName":"p"},{"type":"text","content":"The feature included insights from Pura Dermatology’s Saurabh Lodha, MD, FAAD, who discussed Emrosi’s uniqu...